Xspray Pharma Secures First Patent License Deal with Handa Therapeutics for Dasatinib Commercialization
核心洞察
Xspray Pharma (搜索) has entered into its first patent licensing agreement with Handa Therapeutics (搜索), granting non-exclusive rights to commercialize dasatinib products in the US and selected Asian markets.
The deal will generate up to double-digit royalties on Handa's net proceeds, marking an important milestone in capitalizing on Xspray's intellectual property assets.
Xspray's lead product candidate Dasynoc awaits FDA approval with a PDUFA date of October 7, 2025, and the agreement ensures its launch won't be affected by regulatory exclusivities.
Xspray Pharma (搜索) has announced its first patent licensing agreement with Handa Therapeutics (搜索), granting the partner non-exclusive rights to commercialize dasatinib products in the US market and selected Asian markets. Under the terms of the agreement, Xspray will receive up to double-digit royalties on Handa's net proceeds from the licensed products.
Strategic Milestone for Patent Portfolio
This licensing deal represents the first out-licensing from Xspray's broad patent portfolio and marks an important milestone in capitalizing on the company's intellectual property assets. The agreement validates the value of Xspray's comprehensive patent portfolio, which the company has been building through long-term strategic investments.
"The agreement confirms the value of our patent portfolio and demonstrates that our long-term work to build our comprehensive patent portfolio is paying off," said Per Andersson, CEO of Xspray Pharma (搜索).
Core Strategy Remains Unchanged
Despite this licensing agreement, Xspray's core strategy to develop and commercialize improved protein kinase inhibitor (搜索) (PKI) drugs using its patented HyNap technology platform remains unchanged. The company's lead product candidate Dasynoc awaits FDA approval with a Prescription Drug User Fee Act (PDUFA) date of October 7, 2025.
Andersson expressed confidence in Dasynoc's market positioning, stating, "As for the dasatinib market, I'm convinced that when Dasynoc is launched it will be seen as the premium product in its market segment as it combines pH-independent absorption with lower dose strength and high precision, eliminating sensitivity to all acid-reducing agents."
Regulatory Considerations
The licensing agreement includes provisions that ensure Xspray's planned launch of Dasynoc can proceed without being affected by any United States regulatory exclusivities that may be associated with Handa's dasatinib product. Notably, Handa's dasatinib product has not yet been launched in the market.
Future Licensing Opportunities
While this represents Xspray's first patent licensing deal, the company indicated that further licensing agreements may be considered on a case-by-case basis. This suggests a potential new revenue stream for the Swedish pharmaceutical company as it continues to develop its patent portfolio around cancer (搜索) treatment innovations.
Xspray Pharma (搜索) focuses on developing improved PKIs for cancer (搜索) treatment, leveraging its proprietary HyNap technology platform to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies.